CJC-1295 without DAC + Ipamorelin

The CJC No DAC + Ipamorelin combination is a research formulation that pairs Modified GRF 1-29 with Ipamorelin to investigate synergistic growth hormone (GH) stimulation through two distinct pituitary pathways. Specifically, CJC No DAC targets GHRH receptors on anterior pituitary somatotrophs to amplify GH synthesis and secretion, while Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R / ghrelin receptor). cjc-1295 + ipamorelin

Mechanistically, research demonstrates that these two distinct modes of action function additively or synergistically when co-administered. Consequently, dual receptor engagement produces a significantly greater total GH output than either peptide can achieve as a monotherapy.

Pharmacokinetically, because CJC No DAC lacks the albumin-binding DAC component, it exhibits a short half-life. As a result, co-administration with Ipamorelin yields sharp, physiologically mimetic pulses of growth hormone that closely mirror natural endogenous release rhythms.

In addition, studies have explored the downstream physiological impacts of this combined stimulation on IGF-1 induction, myofibrillar protein synthesis, body composition modulation, slow-wave sleep architecture, and tissue regeneration. Overall, for researchers investigating GH axis dynamics, somatopause, metabolic regulation, and cellular repair, this combination serves as a highly effective and well-characterized experimental model.